Oxazepam
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Oxazepam: From Benzodiazepine Anxiolytic/Sedative Use to Insomnia
One-Sentence Summary
Oxazepam is a short-acting benzodiazepine whose original approved indication is not recorded in this evidence pack (regulatory data gap). The TxGNN model predicts it may be effective for Insomnia, with 0 registered clinical trials and 11 publications currently supporting this direction, several of which directly evaluate oxazepam in insomnia populations.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (TFDA label unavailable — see data gap DG001) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L3 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Oxazepam is a short-acting benzodiazepine. Its pharmacological action works by enhancing GABA-A receptor chloride-channel conductance, producing sedative, anxiolytic, and hypnotic effects. This is the core mechanism shared by the entire benzodiazepine class, not a cross-mechanism inference — sedative-hypnotic activity is a direct, on-target effect of the drug rather than a novel or unexpected pharmacological link.
Because benzodiazepines are already established pharmacologically as sleep-promoting agents, the relationship between oxazepam and insomnia is mechanistically direct rather than speculative. The very high TxGNN score (99.86%) reflects this — it identifies a pharmacologically “obvious” association rather than a genuinely novel repurposing signal.
Currently, a formally documented mechanism-of-action record and original indication text are not available in this evidence pack (data gaps DG001/DG002). Based on known pharmacological class information, however, oxazepam’s GABA-A agonism is well-established, and this mechanism plausibly supports its use in insomnia, consistent with published clinical literature on the drug.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6691478 | 1984 | RCT | The American Journal of Psychiatry | In 14 chronic insomnia patients, oxazepam improved polysomnographic sleep measures without causing the daytime sleepiness seen with flurazepam |
| 29749262 | 2018 | RCT | The Annals of Pharmacotherapy | Randomized trial comparing melatonin and oxazepam for anxiety and sleep quality in STEMI patients post-PCI |
| 17317444 | 2007 | Review | Archives of Gerontology and Geriatrics | Reviews effectiveness and safety of hypnotic drugs, including benzodiazepines, for insomnia in patients over 70 |
| 23330992 | 2013 | Review | Expert Opinion on Drug Metabolism & Toxicology | Reviews pharmacokinetics of anxiolytic/hypnotic drugs including benzodiazepines |
| 29844949 | 2018 | Review | PeerJ | Examines factors associated with long-term benzodiazepine and z-drug use, including oxazepam, in elderly populations |
| 36340306 | 2022 | Review | Journal of Clinical and Experimental Hepatology | Discusses management of alcohol withdrawal syndrome, where insomnia is a key symptom managed with benzodiazepines |
| 15633073 | 2005 | Review | Psychiatrische Praxis | Survey of therapeutic practice for behavioral/sleep disturbances in dementia (BPSD), including benzodiazepine use |
| 23338224 | 1997 | Review | CNS Drugs | Reviews pharmacology of anxiolytic agents in panic disorder, contextualizing benzodiazepine alternatives |
| 6139491 | 1983 | Cohort | JAMA | Reports withdrawal symptoms after substituting oxazepam for long-acting benzodiazepines, including sleep disturbance |
| 39544757 | 2024 | Case Report | American Journal of Translational Research | Case report of a sensory adverse effect with a sedative-related agent (agomelatine), included as background CNS/sleep-drug context |
Denmark Market Information
Oxazepam currently holds no marketing authorisations in Denmark (0 registered, not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between oxazepam (a GABA-A-acting benzodiazepine) and insomnia is pharmacologically direct and well-supported by published literature, including two RCTs specifically evaluating oxazepam in sleep-related outcomes. However, no clinical trials have been registered for this specific indication, and key regulatory safety data (TFDA warnings/contraindications) and formal MOA documentation are currently missing, limiting formal safety review.
To proceed, the following is needed:
- TFDA/SmPC label data on warnings, contraindications, and precautions (DG001, blocking for safety review)
- Formal, sourced mechanism-of-action documentation (DG002)
- Drug-drug interaction (DDI) data, since the current query returned no results
- Assessment of a Danish regulatory pathway, given the drug is not currently marketed in Denmark
- Standard benzodiazepine-class risk evaluation (dependence, withdrawal, elderly fall risk) as part of any formal safety dossier
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.